Amylyx(AMLX) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results CAMBRIDGE, Mass. November 6, 2025 -- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today reported financial and business results for the third quarter ended September 30, 2025. "Entering the final months of 2025, we are focused on execution as we head toward a transformative year in 2026, with topline data expected from the pivotal Phase 3 LUCIDITY trial," said Joshua Cohen and Justin Klee, Co-CEOs of ...